Whalesbook Corporate News
Lupin Gains Tentative US FDA Approval for Pitolisant Tablets Made in India
Lupin Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Pitolisant Tablets in 4.45mg and 17.8mg strengths. These generic tablets are bioequivalent to Harmony Biosciences' Wakix® and will be manufactured at Lupin's Nagpur facility in India.
The company announced the U.S. FDA's tentative approval for the Pitolisant Tablets, which come in 4.45mg and 17.8mg strengths. The drug is designed to be bioequivalent to Wakix®, a medication used to treat narcolepsy. Manufacturing operations for these strengths are located at Lupin's facility in Nagpur, India.
Why This Matters
This tentative approval represents a significant milestone for Lupin as it aims to broaden its product offerings within the U.S. pharmaceutical market. It highlights the company's ability to develop and manufacture complex generic drugs adhering to U.S. regulatory standards. The eventual successful launch of this product is expected to contribute to Lupin's U.S. revenue streams.
The Backstory
Pitolisant, sold by Harmony Biosciences as Wakix®, first received U.S. FDA approval in August 2019. Initially approved for excessive daytime sleepiness (EDS) in adult narcolepsy patients, its indications have since expanded to include cataplexy in adults and EDS in pediatric patients. Harmony Biosciences has reported substantial revenue growth from Wakix®, exceeding $2 billion in cumulative net revenue since its 2019 introduction. Lupin’s Nagpur facility serves as a key manufacturing site for oral solid dosage and injectable products. This facility previously received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the U.S. FDA, signaling satisfactory operations. FDA tentative approvals are generally issued when an application meets all technical requirements but final approval is pending resolution of outstanding patent or exclusivity issues before market entry.
What Changes Now
The tentative approval brings Lupin closer to potentially launching a generic version of Pitolisant in the U.S. The manufacturing will utilize Lupin's established Nagpur facility, reinforcing India's position as a global pharmaceutical manufacturing hub. This addition is set to diversify Lupin's U.S. generics portfolio and revenue streams.
Risks to Watch
The 'tentative' status indicates that final approval hinges on the resolution or expiry of patent and exclusivity periods, which could delay market entry. Although this is a generic drug, the market for narcolepsy treatments is dynamic, and competition from other generics or novel therapies may arise. Lupin must maintain continued adherence to the U.S. FDA's Current Good Manufacturing Practices (cGMP) for ongoing approval. The company has also navigated past regulatory challenges, including a €40 million EU fine for anti-competitive practices and a ₹2.28 crore penalty in India for GST misuse, underscoring the need for rigorous compliance.
Peer Comparison
Lupin operates within India's highly competitive pharmaceutical sector, where major companies actively pursue U.S. market share. Leading Indian generic manufacturers such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Aurobindo Pharma maintain significant U.S. operations and product approvals. Like Lupin, these peers operate multiple USFDA-approved facilities and possess robust generic drug pipelines, reflecting the intense competition for U.S. market approvals. Sun Pharma leads India's pharmaceutical firms by sales, with Dr. Reddy's and Aurobindo Pharma also being major U.S. suppliers.
Market Context
Harmony Biosciences' Wakix® is projected to generate net revenue between $1.0 billion and $1.04 billion for the full year ending December 31, 2026. For the full year ended December 31, 2025, Harmony reported preliminary, unaudited net product revenue for Wakix of approximately $868 million, marking about 21% year-on-year growth.
What to Track Next
Key developments to monitor include the U.S. FDA granting final marketing approval for Pitolisant Tablets, the resolution or expiry of relevant patent and exclusivity periods that clear the way for market entry, and Lupin's specific launch strategy, including pricing and distribution plans. Confirmation of the Nagpur facility's readiness for high-volume commercial production and competitor responses to Lupin's potential entry into the market will also be important to track.